ClinicalTrials.gg
RecruitingNCT04815005HICCUpdated Dec 18, 2025

HoFH, the International Clinical Collaborators Registry

An observational study in Homozygous Familial Hypercholesterolemia, sponsored by University of Pennsylvania. Recruiting at 4 sites in 3 countries. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by University of Pennsylvania · Observational

How we know

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Homozygous Familial Hypercholesterolemia with a site in South Africa — 3 open to participants now, 4 under way, 3 of them phase 3. Homozygous Familial Hypercholesterolemia · South Africa.

Started
2017
with 1 other
Observational
Only one
of the 19
Registered
15th of 19
by date
Lead sponsor
1 of 19
University of Pennsylvania

Among the 19 studies in Homozygous Familial Hypercholesterolemia with a site in South Africa, this one is one of 2 that started in 2017, is the only observational one, and was the 15th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

3 of the 19 studies in Homozygous Familial Hypercholesterolemia with a site in South Africa are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Homozygous Familial Hypercholesterolemia with a site in South Africa, or all of them as a file.
02

Study summary

Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.

Read the detailed description

The HICC registry is an observational, multicenter, international registry collecting de-identified clinical and genetic information from patients with homozygous Familial Hypercholesterolemia (HoFH) worldwide.

Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data reflecting current rather than historic practice, patients who died or were lost to follow-up prior to 2010 are excluded.

Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results of a genetic test), genetic results, (cardiovascular) medical history, relevant family history, physical examination, laboratory measurements, lipid lowering treatment and cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment and at time of best lipid profile (if this is different from time at enrolment). Data are collected using pre-definite electronic case report forms to ensure uniformity of data collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age, etc)

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia

Keywords

  • Homozygous Familial Hypercholesterolemia
  • Autosomal Dominant
  • Hypercholesterolemia
  • Autosomal Recessive Hypercholesterolemia
  • Registry
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry aims to include data from as many patients diagnosed with HoFH as possible. All patients must be living at time of entry into the database or have been deceased within the last 5 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined

Exclusion criteria

Exclusion Criteria:

  • No diagnosis of HoFH
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • HoFH

    Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.

    Other: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.

Interventions

  • OtherDemographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.

    Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.

06

What researchers measure

Primary outcomes

  1. Number of participants entered into the database

    Number of study participants with homozygous familial hypercholesterolemia

    Time frame: Through study completion, an average of 8 years

Secondary outcomes

  1. Untreated and treated LDL-C levels across world income regions

    Number of treated versus number of untreated subjects with relevant LDL-C levels

    Time frame: Through study completion, an average of 8 years

07

Study locations

4 of 4 sites recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Department of Vascular Medicine, Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
  • Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town
    Cape Town, South Africa
    Recruiting
  • c. Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand
    Johannesburg, South Africa
    Recruiting
08

References and documents

Publications

  • Mulder JWCM, Schonck WAM, Tromp TR, Reijman MD, Reeskamp LF, Hovingh GK, Blom DJ, Roeters van Lennep JE. Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia. Atherosclerosis. 2025 May;404:119187. doi: 10.1016/j.atherosclerosis.2025.119187. Epub 2025 Apr 3. PubMed 40250039 ↗
  • Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-Shiba M, Blom DJ, Raal FJ, Cuchel M; Homozygous Familial Hypercholesterolaemia International Clinical Collaborators. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022 Feb 19;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8. Epub 2022 Jan 28. PubMed 35101175 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2017 (actual). Primary completion is estimated for Dec 2026, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2021
First posted
Mar 24, 2021
StartActual
Jan 24, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04815005
Collaborators
University of Amsterdam, University of Cape Town, University of Witwatersrand, South Africa
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Jan 24, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Marina Cuchel, MD, PhD
Contact
mcuchel@pennmedicine.upenn.edu
2156627188
Lauren Vincent, MRA
Contact
laurv@pennmedicine.upenn.edu
2156155448
Marina Cuchel, MD, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion